miRNA profiles in livers with different mass deficits after partial hepatectomy and miR-106b~25 cluster accelerating hepatocyte proliferation in rats

Xiao Xu^{1 §}, MD, PhD, Zhikun Liu^{1 §}, MD, Jianguo Wang^{2, §}, MD, Qi Ling¹, Haiyang Xie², PhD, Haijun Guo², MD, Xuyong Wei², MD, PhD, Lin Zhou², PhD, and Shusen Zheng¹ * MD, PhD, FACS [§] These authors contributed equally to this work

*: corresponding author

 Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

2. Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, China

Supplementary materials



Supplementary Figures

Supplementary Figure 1. Three miRNAs were randomly selected in each expression pattern at 36 hours (up, no-changed, down). Validation of the microarray data was done using real-time PCR on samples of 2/3 *vs.* 1/3PH at 24 and 36 hours after PH. Relative miRNA expression ratios (1/3PH liver considered to be 1) were normalized



against the stably expressed U6 small nucleolar RNA.

Supplementary Figure 2. Venn diagrams. Most of miRNAs whose expression is altered after 1/3 PH are similarly up- or down-regulated after 2/3 PH, except at 6 hours after PH.



Supplementary Figure 3. Venn diagrams were draw according to their type of regulation (up/down), combined with the type of surgery. Most miRNAs showed a biphasic expression pattern.



Supplementary Figure 4. Hepatocyte proliferation was assessed by mmunohistochemistry for Ki67 expression and BrdU incorporation. Staining for both markers showed that 1/3 PH caused a minimal replication; 2/3 induced a robust liver regeneration and a significant peak of DNA replication at 24 hours after PH. Scale bar = $100 \mu m$; original magnification $200 \times$, Olympus.



Supplementary Figure 5. The expression of miR-106b, miR -93, miR -25, miR -92a and miR -101a in normal liver and the remnant liver at serial times after 1/3 and 2/3 PH by real time-PCR. miR-106b, miR-93, miR-25 and miR-92a were found to be up-regulated at 24 and 36 hours after 2/3 PH, and miR-101a down-regulated at 12, 24 and 36 hours after 2/3 PH. The results represent findings obtained from 3 rats. Error bars represent the SD. *, P < 0.05 and **, P < 0.005.



Supplementary Figure 6. The expression of miR-106b, miR-93 and miR-25 in the clusterand sponge-treated rats compared with their respective controls after 2/3PH by real time-PCR. miR-106b, miR-93 and miR-25 were significantly overexpressed in cluster-treated rats than that in the controls and the sponge-treated rats at all times. miR-106b, miR-93 and miR-25 were significantly down-expressed in the sponge-treated rats than that in the controls at the timpoints marked with "*". The results represent obtained from 5 rats. Error bars SD. *, findings represent the Ρ <0.05.



Supplementary Figure 7. The serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and the serum total bilirubin (T.Bil) levels affected by miR106b~25 cluster. ALT, AST, and T.Bil plasma concentration at 96 hours after 2/3 PH was significantly higher in the miR-sponge group compared to the control group and miR-cluster group. There were no significant differences observed among the four groups at other timeponts. The results represent findings obtained from 5 rats. All values are mean \pm SEM. *, *P* < 0.05.



Supplementary Figure 8. The liver weight/body weight ratio in the miR-cluster- and miR-sponge-treated rats compared with their respective controls after 2/3PH. The ratio was significantly higher in miR-cluster overexpressing rats than the controls only at 36h after 2/3PH and remained significant lower in the miR-sponge-treated rats than the controls and the miR-cluster-treated rats from 24h to 96h after 2/3PH. *, P < 0.05 miR-cluster vs cluster control; #, P < 0.05 miR-sponge vs sponge control; \triangle , P < 0.05 miR-sponge vs miR-cluster.



Supplementary Figure 9. The role of miR106b/25 on cyclins (Cdk6, Ccnb1, Ccnb2, Ccne1 and Cdc25) in the tissues of animals using real-time PCR at 24 hours after PH. The miR-106~25 cluster affect the expression of Ccnb1 and Cdc25.

Supplementary Tables

Supplementary Table 1. List of miRNAs detected in liver tissues using microarrays. All the data were normalized and FDR=20%. Normal livers: sm79normal_NS, sm65normal_NS, sm75normal_NS; 6 hours after 1/3 PH: s01m62_NS, s01m64_NS; 6 hours after 2/3 PH: s02m67_NS, s02m70B_NS, s02m76_NS; 12 hours after 1/3 PH: s03m2_NS, s03m5m_NS, s03m6_NS; 12 hours after 2/3 PH: s04m3_NS, s04m7_NS, s04m12B_NS; 24 hours after 1/3 PH: s05m20_NS, s05m23_NS, s05m24_NS; 24 hours after 2/3 PH: s06m26_NS, s06m29B_NS, s06m31B_NS; 36 hours after 1/3 PH: s07m45B_NS, s07m46_NS, s07m47_NS; 36 hours after 2/3 PH: s08m37B_NS, s08m39B_NS, s08m40_NS.

systematic_	sm7	sm6	sm7	s01	s01	s02	s02	s02	s03	s03	s03	s04	s04	s04	s05	s05	s05	s06	s06	s06	s07	s07	s07	s08	s08	s08
name	9nor	5nor	5nor	m62	m64	m67	m70	m76	m2_	m5	m6_	m3_	m7_	m12	m20	m23	m24	m26	m29	m31	m45	m46	m47	m37	m39	m40
	mal	mal	mal	_NS	_NS	_NS	B_N	_NS	NS	m_	NS	NS	NS	B_N	_NS	_NS	_NS	_NS	B_N	B_N	B_N	_NS	_NS	B_N	B_N	_NS
	_NS	_NS	_NS				s			NS				s					s	s	s			s	S	
rno-let-7a	10.5	10.5	10.5	10.5	10.5	10.5	10.5	10.5	10.7	10.7	10.7	10.7	10.7	10.7	10.5	10.5	10.5	10.7	10.5	10.7	10.5	10.5	10.5	10.7	10.7	10.7
	1	1	1	1	1	1	1	1	2	2	2	2	2	2	1	1	1	2	1	2	1	1	1	2	2	2
rno-let-7b	10.0	9.79	10.0	9.91	10.0	10.0	10.0	9.79	9.91	9.91	9.91	9.91	9.91	9.91	9.66	9.79	9.79	9.91	9.79	9.79	9.91	10.0	9.79	9.91	9.79	9.66
	4		4		4	4	4															4				
rno-let-7b*	0.49	-3.3	3.30	-3.2	2.96	4.25	-3.1	-3.2	4.04	-2.8	3.35	3.56	3.63	-3.3	2.38	4.01	-3.3	0.27	3.27	4.25	4.08	-3.2	3.38	-2.9	3.35	-3.2
		2		2			4	9		5				0			1					6		8		7
rno-let-7c	9.91	9.91	9.79	10.0	9.91	9.91	9.91	10.0	10.0	10.0	10.0	10.0	10.0	10.0	9.79	10.0	9.91	9.79	9.91	9.91	10.0	9.79	9.91	9.66	9.91	9.79
				4				4	4	4	4	4	4	4		4					4					
rno-let-7d	8.82	8.99	9.14	8.82	8.82	9.14	8.82	8.99	8.82	8.99	8.82	8.82	8.82	8.82	8.82	8.99	8.67	8.67	8.67	8.82	8.82	8.82	8.82	8.82	8.82	8.67
rno-let-7e	6.40	6.19	6.15	6.33	5.89	6.40	6.62	6.49	6.73	7.06	6.49	6.68	6.93	6.55	6.25	6.49	6.49	6.49	6.40	6.25	6.55	6.15	6.15	5.93	5.98	6.09
rno-let-7f	10.2	10.2	10.2	10.2	10.2	10.2	10.2	10.2	10.2	10.2	10.2	10.2	10.5	10.2	10.2	10.2	10.2	10.0	10.2	10.2	10.2	10.2	10.2	10.2	10.2	10.2

	_	_		_		_	_			_	_	_		_		_			-		-	_	_	_	-	_
	6	6	6	6	6	6	6	6	6	6	6	6	1	6	6	6	6	4	6	6	6	6	6	6	6	6
rno-let-7i	7.80	7.39	7.67	7.80	7.51	7.80	7.88	7.61	7.88	7.74	7.88	7.80	8.16	7.56	7.74	7.74	7.88	7.96	7.80	7.61	7.74	7.67	7.61	7.96	7.88	7.56
rno-miR-1*	1.96	-3.3	0.49	2.24	-3.2	3.59	-3.1	-3.2	2.38	-2.8	3.27	4.12	3.05	-3.3	3.53	3.01	-3.3	2.44	3.56	3.16	3.53	1.15	3.33	2.57	2.96	-3.2
		2			1		4	9		5				0			1									7
rno-miR-10	2.61	2.61	1.15	2.90	-3.2	2.48	-3.1	3.12	3.45	-2.8	2.44	3.19	3.16	2.61	2.24	3.48	3.42	3.01	2.38	2.84	2.38	3.12	0.72	-0.0	0.72	2.38
0					1		4			5														3		
rno-miR-10	4.57	5.39	5.16	4.61	6.68	4.39	3.12	4.97	4.57	-2.8	4.30	3.16	3.38	4.35	5.01	5.16	5.01	4.65	4.74	4.61	5.11	4.74	5.28	4.25	4.44	4.48
1a										5																
rno-miR-10	7.16	7.80	7.80	7.44	6.62	6.99	6.86	7.28	7.16	7.16	7.34	7.11	6.68	7.28	7.96	7.80	7.56	7.67	7.67	7.67	7.80	7.61	7.80	7.67	7.80	7.80
1b																										
rno-miR-10	6.19	6.15	5.98	6.15	5.78	6.25	6.25	6.25	6.33	5.49	6.25	6.25	6.33	6.40	6.15	6.25	6.19	6.25	6.15	6.33	6.49	6.09	6.33	5.98	6.15	6.25
3																										
rno-miR-10	5.28	5.34	5.49	5.16	4.35	4.87	4.53	5.16	4.97	4.71	5.01	4.93	5.22	5.22	5.67	5.54	5.39	5.73	5.98	5.98	5.49	4.97	5.58	6.04	6.09	5.73
6b																										
rno-miR-10	6.62	6.68	6.55	6.40	5.83	6.68	6.55	6.62	6.62	6.15	6.55	6.73	6.73	6.73	6.68	6.73	6.62	6.73	6.62	6.68	6.62	6.73	6.62	6.68	6.79	6.62
7																										
rno-miR-10	6.79	6.93	6.79	6.79	6.19	6.86	7.16	6.99	6.86	6.79	6.73	6.79	7.06	6.62	6.62	6.68	6.68	6.62	6.55	6.55	6.68	6.62	6.86	6.19	6.19	6.33
a-5p																										
rno-miR-12	14.6	14.6	14.6	14.6	14.6	14.6	14.6	14.6	14.6	13.3	14.6	14.6	14.6	14.6	14.6	14.6	14.6	14.6	14.6	14.6	14.6	14.6	14.6	14.6	14.6	14.6
2	7	7	7	7	7	7	7	7	7	9	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7
rno-miR-12	7.11	7.67	7.44	7.16	6.79	7.34	7.44	7.80	7.34	8.47	7.51	7.39	7.39	7.74	7.34	7.34	7.34	6.86	7.28	7.34	7.39	7.16	7.34	7.16	7.24	7.74
2*																										
rno-miR-12	7.34	7.06	7.16	7.39	7.24	7.24	7.56	7.24	7.39	7.96	7.61	7.96	7.96	7.61	7.24	6.99	6.99	7.11	7.34	7.74	6.99	7.74	7.44	7.51	7.51	7.39
24																										
rno-miR-12	3.53	-3.3	3.72	2.61	3.05	3.68	3.23	-3.2	4.08	-2.8	3.45	4.30	5.34	-3.3	2.61	3.63	-3.3	3.53	3.93	4.04	3.56	4.04	4.04	3.38	3.66	-3.2
49		2						9		5				0			1									7

rno-miR-12	3.38	-0.3	3.48	4.35	-3.2	-3.2	4.25	2.96	1.66	-2.8	4.65	2.57	4.12	4.77	2.48	-0.2	3.35	4.77	-3.2	1.15	1.66	5.06	3.42	5.06	3.72	4.81
5a-3p		3			1	6				5						3			4							
rno-miR-12	4.21	3.53	3.66	4.12	3.66	4.12	4.08	4.01	4.35	4.39	3.97	3.63	3.93	3.97	3.93	3.97	4.21	3.66	3.72	4.08	4.12	3.63	3.68	3.33	3.33	3.38
5a-5p																									ľ	
rno-miR-12	6.93	7.24	6.93	6.93	6.25	7.06	7.28	7.39	7.67	7.11	7.16	7.34	7.28	7.67	7.06	7.24	7.39	6.99	6.86	7.16	7.16	6.99	6.79	6.33	6.73	7.11
5b-5p																									ľ	
rno-miR-12	8.67	8.67	8.57	8.57	8.67	8.57	8.57	8.57	8.47	8.16	8.67	8.47	8.57	8.47	8.57	8.67	8.57	8.57	8.57	8.47	8.57	8.67	8.57	8.29	8.47	8.47
6																									ľ	
rno-miR-12	2.24	1.41	-0.3	2.84	-3.2	-3.2	-3.1	1.41	-3.2	-2.8	-2.3	-3.2	-3.2	1.15	-3.2	-3.2	1.66	-0.3	-3.2	-3.2	-3.2	-3.2	2.31	-1.7	-0.2	-3.2
8			3		1	6	4		3	5	3	9	9		5	9		3	4	5	9	6		1	3	7
rno-miR-13	6.55	6.55	6.49	6.73	5.98	6.62	6.73	6.93	6.99	6.93	6.86	6.86	6.86	6.99	6.73	6.62	6.79	6.79	6.79	6.62	6.73	6.33	6.55	7.34	6.93	7.06
0a																									ľ	
rno-miR-13	5.01	3.30	2.84	5.89	4.25	2.96	6.15	6.09	3.27	4.44	5.98	4.97	3.23	6.49	4.77	1.41	5.78	5.78	4.61	2.54	2.31	6.19	4.74	6.86	5.22	5.83
9-3p																									ľ	
rno-miR-14	5.11	5.11	5.11	4.77	4.44	4.65	4.87	4.87	5.22	5.45	4.53	4.61	4.53	5.01	4.93	5.06	5.22	4.71	5.11	4.97	5.22	4.81	5.11	4.21	4.48	4.61
0																									ľ	
rno-miR-14	3.45	4.35	4.04	3.45	3.33	3.48	3.53	3.66	4.25	4.17	2.94	2.96	3.56	3.68	3.23	3.68	3.97	3.42	3.09	3.45	3.72	3.38	3.19	2.38	2.90	3.45
0*																									ľ	
rno-miR-14	5.06	5.73	5.34	5.01	4.30	4.71	3.66	4.74	4.53	4.77	3.72	3.97	4.57	5.16	4.71	4.74	5.28	3.63	4.77	3.27	5.16	4.39	5.01	4.12	4.35	4.35
2-3p																									ľ	
rno-miR-14	7.24	7.16	7.06	6.86	6.49	7.16	6.99	7.16	7.24	7.24	6.99	7.24	7.24	7.24	7.11	7.16	7.61	7.39	7.16	6.93	6.93	7.39	7.11	6.73	7.16	6.73
3																									ľ	
rno-miR-14	5.73	5.93	5.67	5.54	5.11	6.09	6.09	6.04	5.89	5.98	5.58	5.89	6.25	5.89	5.45	5.58	5.67	5.28	5.67	5.22	6.33	5.28	5.83	4.71	5.73	5.54
6a																									ľ	
rno-miR-14	3.09	4.39	4.01	2.96	3.09	2.94	3.27	4.21	2.84	-2.8	-0.7	-3.2	2.24	2.90	2.90	3.12	4.25	2.48	2.84	2.38	2.54	3.09	2.90	0.49	2.61	3.53
8b-3p										5	3	9													l l	1

rno-miR-15	4.12	4.25	4.17	3.93	3.30	4.08	3.38	3.93	3.93	-2.8	3.05	3.38	4.17	4.17	3.45	3.59	4.01	3.33	3.38	3.23	3.59	3.35	3.35	2.61	3.19	3.30
0										5																
rno-miR-15	4.93	4.93	5.58	4.97	3.97	4.97	5.06	4.35	5.01	-2.8	5.67	4.87	5.49	5.06	5.28	5.22	4.65	5.34	4.65	5.45	4.97	5.67	4.93	5.73	5.34	5.11
0*										5																
rno-miR-15	6.49	6.49	6.40	6.49	5.93	6.55	6.79	6.79	6.04	6.68	5.78	6.40	6.09	5.93	5.89	6.19	6.15	6.15	5.89	6.04	5.78	6.55	6.49	5.54	5.89	5.93
1																										
rno-miR-15	3.12	3.68	3.45	3.23	2.48	3.05	3.09	3.42	3.97	-2.8	3.01	3.30	3.12	3.42	3.72	3.35	4.04	3.16	3.48	3.48	3.63	3.27	3.53	2.54	3.59	4.01
2										5																
rno-miR-15	7.39	7.28	7.28	7.74	7.16	7.39	7.67	7.44	7.44	7.56	7.67	7.44	7.80	7.80	7.51	7.51	7.51	7.44	8.04	7.56	7.11	7.24	7.28	8.57	8.57	8.57
b																										
rno-miR-16	8.99	8.47	8.99	8.99	8.99	8.82	8.99	8.47	9.14	8.67	8.99	8.99	9.14	9.14	9.14	9.14	9.14	8.99	8.99	9.14	9.14	8.99	9.14	9.14	9.46	8.99
rno-miR-17	2.54	3.23	2.48	3.09	2.54	3.16	-3.1	3.05	3.12	-2.8	2.90	3.48	0.27	2.84	3.33	2.96	3.05	4.35	3.97	4.21	3.05	2.48	2.54	3.93	4.01	4.04
-5p							4			5																
rno-miR-18	3.59	4.21	2.96	3.63	3.35	3.63	3.72	4.39	3.66	-2.8	2.61	3.12	3.27	3.53	3.01	3.16	4.30	2.90	3.30	3.35	3.16	3.23	3.27	0.72	2.24	3.01
1a										5																
rno-miR-18	-3.3	0.27	-0.7	-3.2	-3.2	-3.2	-3.1	-3.2	-3.2	-2.8	-2.1	-3.2	-3.2	1.66	3.12	1.15	2.31	3.97	4.08	3.97	2.84	-3.2	-3.2	4.17	4.12	3.66
а	0		3	2	1	6	4	9	3	5	6	9	9									6	9			
rno-miR-19	-1.1	-3.3	1.66	2.31	2.94	3.45	2.96	-3.2	2.31	-2.8	1.15	3.33	2.54	-3.3	3.35	2.94	-3.3	-2.1	3.23	2.48	3.30	-3.2	-0.0	-0.7	-1.7	-3.2
1*	3	2						9		5				0			1	3				6	3	3	1	7
rno-miR-19	9.66	10.0	9.91	9.79	9.79	9.66	9.79	9.91	9.66	9.79	9.46	9.46	9.79	9.79	9.91	9.91	10.0	9.46	9.66	9.66	9.79	9.91	10.0	9.79	9.66	9.91
2		4															4						4			
rno-miR-19	6.25	6.79	6.86	6.04	5.49	5.83	5.73	6.33	6.40	7.67	6.33	5.93	5.78	6.93	6.93	6.79	6.55	6.40	6.73	6.79	6.79	6.25	6.68	6.49	6.40	6.68
3																										
rno-miR-19	7.51	7.61	7.61	7.56	7.28	7.44	7.51	7.34	7.80	7.61	7.74	7.74	7.51	7.88	7.80	7.88	7.44	7.28	7.56	7.80	7.88	7.51	7.74	7.44	7.61	7.67
4																										
rno-miR-19	3.63	4.01	3.01	3.27	3.12	3.53	-3.1	3.33	3.53	4.01	3.42	3.59	3.30	4.01	4.01	4.17	4.44	5.22	4.71	4.35	3.27	3.33	3.63	4.77	4.30	4.21

49							4																			
rno-miR-19	8.16	7.44	8.04	8.04	7.88	7.88	8.16	7.88	7.74	7.28	7.80	7.56	7.74	7.51	7.61	7.67	7.24	7.61	7.51	7.51	7.67	7.96	7.56	7.24	7.28	7.24
5																										
rno-miR-19	5.45	5.54	5.28	5.45	4.61	5.67	5.39	5.67	5.93	5.28	4.77	5.45	5.89	5.28	5.39	5.49	6.33	6.33	5.58	5.78	5.67	5.49	5.54	5.22	5.11	5.01
9a-3p																										
rno-miR-19	3.05	3.12	0.27	3.16	-3.2	2.61	-3.1	3.19	4.01	-2.8	0.27	2.90	2.48	2.38	2.94	3.38	4.48	3.19	3.12	3.33	3.09	2.54	2.38	2.31	1.41	3.12
9a-5p					1		4			5																
rno-miR-19	2.57	4.97	4.74	3.35	2.31	2.57	-3.1	4.12	2.94	-2.8	2.84	3.01	-0.0	3.23	3.56	3.53	3.66	4.39	4.44	3.53	4.25	3.45	3.56	4.65	4.71	4.77
a							4			5			3													
rno-miR-19	8.29	8.82	8.67	8.47	7.74	7.96	7.80	8.04	7.96	7.51	8.04	8.04	7.61	8.04	8.67	8.16	8.29	8.82	8.82	8.67	8.47	8.47	8.47	8.67	8.67	8.82
b																										
rno-miR-20	2.38	2.84	-1.5	-3.2	-3.2	-3.2	-3.1	2.90	3.23	-2.8	2.38	2.38	1.15	2.94	3.19	3.19	3.59	3.35	2.57	3.30	3.38	2.90	1.96	3.27	3.48	3.16
0a			2	2	1	6	4			5																
rno-miR-20	4.53	4.71	3.38	4.25	3.59	4.21	4.57	4.93	5.49	6.04	5.34	5.11	4.48	4.71	5.06	5.34	5.16	5.16	4.87	5.34	5.34	4.35	4.01	5.83	5.78	5.06
0b																										
rno-miR-20	5.83	5.45	5.89	6.25	5.16	5.58	6.33	6.15	5.58	4.21	6.62	6.33	5.45	6.15	6.49	5.78	5.98	6.68	5.93	5.89	5.54	6.86	6.09	7.11	6.62	6.55
2*																										
rno-miR-20	7.06	6.86	6.99	7.28	6.40	7.11	7.06	6.68	7.06	6.73	7.44	7.61	6.62	6.79	7.39	7.11	6.73	8.04	7.88	7.96	6.86	7.11	6.93	8.04	7.67	7.51
а																										
rno-miR-20	4.87	5.16	5.06	4.93	4.48	5.39	4.30	4.81	5.16	4.65	5.06	5.54	4.21	4.97	5.22	5.11	4.97	5.83	5.83	5.93	5.01	4.61	4.81	5.28	5.45	5.34
b-5p																										
rno-miR-21	11.4	11.7	11.7	12.1	11.4	11.7	11.7	11.7	11.2	11.4	11.7	11.7	11.0	11.7	12.1	11.7	11.7	12.4	12.1	12.4	12.1	12.1	12.1	12.4	12.1	11.7
	3	4	4	5	3	4	4	4	1	3	4	4	2	4	5	4	4	2	5	2	5	5	5	2	5	4
rno-miR-21	3.56	4.12	3.33	3.38	3.38	2.84	3.42	4.08	3.16	-2.8	2.57	2.84	2.90	3.05	3.48	3.27	3.38	3.12	3.19	3.72	2.61	2.96	3.01	3.30	2.48	2.90
0										5																
rno-miR-21	5.93	5.06	6.09	6.09	5.22	5.54	6.19	5.89	5.45	3.93	6.93	6.19	5.28	5.73	5.83	5.67	5.58	6.04	5.49	4.93	5.45	6.68	6.19	6.62	6.33	6.40

r	1				1	1			1	1		1	1	1		1	1	1	1	1	1	1	1		-	
2																										
rno-miR-21	4.01	3.97	3.05	3.68	3.23	3.97	3.68	4.30	4.77	4.30	3.16	3.45	4.25	4.08	3.42	4.65	5.06	4.48	3.53	4.77	3.66	3.59	3.05	3.97	3.16	3.72
4																										
rno-miR-22	10.7	11.0	11.0	11.0	10.7	10.7	10.7	10.7	10.5	11.0	10.5	10.5	10.2	10.5	10.7	10.7	11.0	10.5	10.7	10.5	10.7	11.2	10.7	10.5	10.5	10.5
	2	2	2	2	2	2	2	2	1	2	1	1	6	1	2	2	2	1	2	1	2	1	2	1	1	1
rno-miR-22	-0.0	1.66	-3.3	-3.2	-3.2	1.15	-3.1	2.94	2.44	-2.8	-1.7	0.49	-3.2	-0.7	-3.2	0.27	2.48	0.49	1.96	2.24	-3.2	-3.2	-3.2	1.41	0.27	2.94
1	3		2	2	1		4			5	1		9	3	5						9	6	9			
rno-miR-22	5.49	5.83	5.45	5.93	5.54	5.89	5.54	5.73	5.34	6.55	5.49	5.49	5.83	5.83	5.54	5.39	5.89	4.74	5.45	5.73	5.83	5.01	5.39	5.58	5.39	5.28
3																										
rno-miR-23	7.28	7.56	7.24	7.11	7.11	7.51	7.34	7.67	7.51	7.88	7.06	7.16	7.34	7.44	6.86	7.06	7.74	7.16	6.99	7.06	7.28	7.06	7.24	6.79	7.06	7.16
а																										
rno-miR-23	8.47	8.57	8.29	8.29	8.29	8.47	8.47	8.82	8.57	9.14	8.47	8.67	8.47	8.67	8.29	8.29	8.82	8.29	8.29	8.29	8.29	8.29	8.29	8.16	8.16	8.29
b																										
rno-miR-24	7.74	7.51	7.39	7.51	7.39	7.74	7.61	7.74	7.61	7.39	7.39	7.51	7.67	7.39	7.44	7.56	7.67	7.51	7.39	7.44	7.51	7.44	7.51	7.39	7.44	7.44
rno-miR-25	6.09	6.04	5.78	5.98	5.45	5.98	6.04	5.98	6.19	5.54	6.19	6.04	6.40	6.09	6.04	5.89	5.93	6.55	6.68	6.49	6.09	5.73	5.73	6.40	6.55	6.49
rno-miR-26	8.57	9.14	8.82	8.67	8.57	8.67	8.67	8.67	8.67	8.82	8.57	8.57	8.67	8.57	8.47	8.57	8.47	8.16	8.16	8.16	8.67	8.57	8.67	7.80	8.04	8.04
а																										
rno-miR-26	7.88	8.16	7.88	7.88	7.67	8.04	8.04	8.16	8.04	8.04	7.96	7.88	8.04	7.96	7.88	7.96	7.96	7.56	7.74	7.88	8.04	7.88	8.16	7.56	7.74	7.88
b																										
rno-miR-27	6.86	6.62	6.73	6.62	6.04	6.49	6.40	6.55	6.79	7.34	6.40	6.62	6.55	6.68	6.79	6.86	6.93	7.06	7.06	7.11	7.24	6.93	6.99	6.93	6.99	6.93
а																										
rno-miR-27	7.56	7.34	7.34	7.24	6.99	7.56	7.39	7.56	7.56	7.44	7.56	7.67	7.56	7.34	7.56	7.44	7.28	7.34	7.61	7.39	7.44	7.34	7.39	7.06	7.39	7.28
b																										
rno-miR-28	4.74	5.01	5.01	4.71	3.72	5.01	4.35	5.01	4.44	4.81	4.17	4.04	4.39	4.30	4.30	4.93	4.77	4.44	5.01	4.44	4.81	4.71	4.97	4.53	4.93	4.65
rno-miR-29	4.81	4.61	4.97	4.81	4.01	4.53	4.71	4.25	4.61	-2.8	4.97	5.06	4.77	4.65	4.87	5.01	4.35	4.81	4.53	4.71	4.74	5.39	4.87	4.93	5.06	4.74
0										5																1

rno-miR-29	2.48	-3.3	0.72	2.48	-3.2	3.56	-3.1	-3.2	2.90	-2.8	3.30	3.93	4.61	-3.3	2.44	3.33	-3.3	3.23	2.94	3.05	3.42	3.93	3.93	3.05	3.23	-3.2
6*		2			1		4	9		5				0			1									7
rno-miR-29	-3.3	-3.3	-1.7	-3.2	2.61	3.23	-3.1	-3.2	1.96	-2.8	0.72	-0.2	3.09	-3.3	1.15	3.09	-3.3	-0.2	1.66	1.66	2.90	-3.2	-0.3	-3.3	-1.9	-3.2
8	0	2	1	2			4	9		5		3		0			1	3				6	3	2	2	7
rno-miR-29	4.44	3.33	4.39	4.57	4.65	5.22	4.44	3.45	4.74	5.89	4.44	5.28	5.06	3.27	5.16	4.87	3.16	4.21	4.97	5.16	5.06	4.65	4.77	4.01	4.65	3.33
85																										
rno-miR-29	9.46	9.66	9.66	9.66	9.46	9.46	9.14	9.46	9.46	8.57	9.14	9.14	8.99	9.46	9.46	9.46	9.46	9.66	9.46	9.46	9.66	9.46	9.66	9.46	9.14	9.14
а																										
rno-miR-29	6.99	8.04	7.56	7.06	6.15	6.79	6.49	6.73	6.68	6.49	6.68	6.49	6.49	7.06	7.28	7.39	7.11	7.80	7.44	7.24	7.61	7.56	7.67	7.88	7.56	7.61
b																										
rno-miR-29	7.61	7.88	7.74	7.67	6.73	7.28	6.93	7.11	7.11	6.09	7.11	6.99	6.79	7.11	7.67	7.61	7.16	7.74	7.24	7.28	7.56	8.04	8.04	7.61	7.34	7.34
с																										
rno-miR-30	3.72	3.45	4.12	4.04	4.08	4.74	4.21	3.27	4.39	5.83	4.08	4.44	4.87	3.72	4.44	4.53	3.30	3.68	4.35	4.65	4.65	4.30	4.17	3.53	4.04	3.56
85																										
rno-miR-30	6.68	6.99	7.11	6.68	6.09	6.73	6.68	6.86	6.93	6.62	6.79	6.93	6.99	6.86	6.99	6.93	6.86	6.93	6.93	6.86	7.06	6.79	7.06	6.55	6.86	6.86
а																										
rno-miR-30	4.65	4.77	4.48	4.48	3.56	4.77	4.93	5.11	4.93	5.73	4.39	4.53	4.44	4.81	4.53	4.61	4.81	4.04	4.57	4.53	4.57	4.25	4.65	3.59	3.93	4.25
a*																										
rno-miR-30	-1.5	-1.5	-1.9	-3.2	-3.2	0.72	2.84	2.38	2.24	-2.8	-1.1	-0.3	2.31	2.48	-3.2	-0.3	1.41	-1.7	-3.2	-3.2	-0.2	-3.2	-0.2	-2.9	-3.3	2.44
b-3p	2	2	2	2	1					5	3	3			5	3		1	4	5	3	6	3	8	1	
rno-miR-30	6.33	6.40	6.33	5.83	5.73	6.33	5.67	6.40	6.55	6.19	5.83	6.15	6.19	5.98	6.40	6.33	6.40	5.54	6.09	6.40	6.40	5.58	6.25	5.45	6.25	5.89
b-5p																										
rno-miR-30	5.89	6.33	6.04	5.78	5.34	6.04	5.93	6.19	6.25	6.86	6.04	5.98	6.04	6.19	6.09	6.04	6.25	5.93	6.25	5.83	6.19	5.89	6.04	5.89	6.04	6.15
с																										
rno-miR-30	5.58	6.25	5.73	5.49	5.06	5.93	5.83	5.93	5.73	6.40	5.54	5.78	5.67	6.25	5.93	5.98	6.09	5.67	5.78	6.09	6.15	5.78	5.67	5.49	5.83	6.19
d																										1

rno-miR-30	5.54	5.98	5.83	5.58	4.57	5.34	4.97	5.45	5.39	5.01	5.22	5.22	4.93	5.67	5.73	5.73	5.73	5.49	5.73	5.39	5.73	5.54	5.78	5.34	5.49	5.45
е																										
rno-miR-30	3.23	3.66	3.19	3.30	3.27	3.30	3.59	3.68	3.56	4.74	2.48	2.54	2.96	3.35	3.09	2.84	3.33	2.31	3.05	2.90	2.48	3.05	3.09	2.24	1.15	3.42
e*																										
rno-miR-31	5.39	5.49	5.54	5.11	4.71	5.73	5.22	5.58	5.67	4.61	5.39	5.73	5.54	5.58	5.78	5.45	5.49	5.58	5.54	5.67	5.58	5.16	5.49	5.16	5.58	5.67
rno-miR-31	-3.3	2.31	-0.0	-3.2	-3.2	2.31	-3.1	2.57	2.96	-2.8	0.49	1.96	-3.2	2.31	-3.2	-3.2	1.15	0.72	2.31	-3.2	0.27	-3.2	-3.2	-1.5	-0.0	2.61
*	0		3	2	1		4			5			9		5	9				5		6	9	2	3	
rno-miR-32	3.48	4.17	4.44	3.05	-3.2	2.38	3.05	3.35	3.01	-2.8	4.12	1.66	3.42	3.59	4.08	4.30	3.45	4.08	3.63	3.09	3.97	4.53	4.08	4.30	4.21	4.30
0					1					5																
rno-miR-32	5.34	5.22	5.39	5.34	4.74	5.28	5.16	5.54	5.54	4.97	5.11	5.16	5.39	5.39	5.34	5.28	5.45	5.06	5.34	5.54	5.28	4.93	5.16	4.61	4.74	4.71
2																										
rno-miR-32	5.98	5.78	6.62	5.73	5.28	6.15	5.89	5.22	6.09	5.11	6.15	6.09	6.15	5.34	6.33	6.55	5.34	5.89	6.04	6.19	6.04	5.98	5.98	6.25	6.49	6.04
4-3p																										
rno-miR-32	2.90	-1.7	-0.2	-3.2	-3.2	2.44	3.16	2.24	2.48	-2.8	-0.0	2.24	1.96	2.54	-3.2	0.72	-1.1	-0.0	-3.2	-3.2	0.49	-3.2	-3.2	-1.9	-3.3	1.41
8a		1	3	2	1					5	3				5		3	3	4	5		6	9	2	1	
rno-miR-33	1.66	0.72	-2.3	-3.2	-3.2	-3.2	-3.1	1.96	-3.2	-2.8	-3.3	-3.2	-3.2	-3.3	-3.2	-3.2	-1.5	-3.3	-3.2	-3.2	-3.2	2.31	-3.2	-3.3	-3.3	-3.2
1			3	2	1	6	4		3	5	2	9	9	0	5	9	2	1	4	5	9		9	2	1	7
rno-miR-33	2.44	4.04	3.09	3.33	-3.2	3.19	3.35	4.61	3.68	3.97	3.48	3.23	3.33	3.56	3.16	3.42	4.53	2.57	3.16	3.38	3.19	2.44	3.12	3.19	3.42	3.19
5					1																					
rno-miR-33	3.93	3.56	3.56	3.66	-3.2	1.66	-3.1	3.48	-3.2	-2.8	-2.3	-3.2	-3.2	-3.3	-3.2	-3.2	2.61	-3.3	-3.2	-3.2	-3.2	-3.2	3.59	-3.3	-3.3	-3.2
8					1		4		3	5	2	9	9	0	5	9		1	4	5	9	6		2	1	7
rno-miR-34	3.30	3.48	2.94	3.12	3.01	3.01	3.33	3.09	3.35	-2.8	1.96	1.41	4.35	4.12	2.84	3.05	3.93	1.96	2.61	3.01	4.35	2.84	2.61	-1.1	2.38	2.57
2-3p										5														3		
rno-miR-34	4.25	4.30	4.61	5.39	2.24	3.12	4.77	4.44	3.63	-2.8	4.93	4.01	2.94	4.93	4.74	4.44	4.57	5.11	4.12	4.17	4.39	5.34	4.71	5.11	4.81	5.22
5-3p										5																
rno-miR-34	4.17	4.65	4.57	4.21	3.53	4.35	3.97	4.53	4.30	4.35	3.93	4.57	3.35	4.21	4.25	4.08	4.71	4.53	4.93	4.81	4.17	4.08	4.35	4.81	4.77	4.87

-																										
5-5p																										
rno-miR-34	3.35	3.01	3.23	3.53	2.84	2.54	3.45	3.97	2.61	-2.8	3.68	3.09	0.72	4.04	2.54	2.57	3.23	2.84	-3.2	-3.2	2.44	3.72	3.23	3.66	2.84	4.08
7										5									4	5						
rno-miR-34	5.16	5.28	5.22	5.28	4.87	5.16	5.49	5.28	5.98	5.34	6.09	5.83	5.58	5.49	6.19	6.15	5.83	6.09	6.49	6.73	6.25	5.11	5.89	7.28	6.68	6.99
а																										
rno-miR-35	2.96	3.16	2.31	2.94	2.38	3.09	3.48	3.38	3.30	-2.8	2.54	2.48	2.44	3.19	-3.2	2.38	2.96	2.24	2.54	2.94	2.57	2.94	2.57	1.96	2.31	3.23
2										5					5											
rno-miR-35	-3.3	-3.3	2.57	-3.2	2.57	4.01	-3.1	-3.2	2.57	-2.8	3.12	4.21	3.48	-3.3	3.97	3.56	-3.3	3.05	3.42	4.01	4.04	2.24	1.41	2.48	3.12	-3.2
44	0	2		2			4	9		5				0			1									7
rno-miR-35	-0.3	-3.3	3.53	3.59	3.63	4.30	-3.1	-3.2	3.72	-2.8	3.53	4.08	3.72	-3.3	4.39	4.04	-3.3	3.27	4.17	4.30	4.21	3.68	3.72	3.01	3.63	-3.2
49	3	2					4	9		5				0			1									7
rno-miR-35	4.30	4.87	4.81	4.44	6.55	4.17	4.04	4.48	4.71	-2.8	4.61	4.25	3.66	4.25	5.11	4.71	4.93	4.93	5.28	5.01	4.93	4.48	5.22	4.87	5.16	5.16
59-5p										5																
rno-miR-35	0.72	2.38	3.59	3.72	-3.2	-3.2	3.19	2.31	-3.2	-2.8	4.01	-3.2	-3.2	3.66	-3.2	1.66	0.49	4.25	-3.2	-3.2	-3.2	4.44	1.66	4.44	3.56	4.12
61-5p					1	6			3	5		9	9		5				4	5	9					
rno-miR-35	4.71	3.93	4.65	5.06	3.93	4.04	5.11	4.04	4.21	-2.8	5.28	4.74	4.01	5.11	4.81	4.25	4.12	5.39	4.39	4.48	3.93	5.83	4.61	6.15	5.01	5.39
62										5																
rno-miR-35	3.19	2.96	3.42	-3.2	-3.2	3.38	-3.1	-3.2	-3.2	4.87	3.33	4.17	4.04	3.16	2.31	3.30	2.84	3.30	3.59	3.68	3.33	3.56	3.48	3.23	3.27	1.96
73-3p				2	1		4	9	3																	
rno-miR-35	7.44	5.58	6.19	7.34	7.06	7.61	7.24	5.83	6.49	4.48	7.28	7.06	7.11	5.45	5.58	6.09	4.17	4.97	5.39	5.58	5.98	6.40	6.40	6.09	4.53	4.93
88																										
rno-miR-36	3.33	4.08	3.97	3.42	3.16	3.35	3.63	3.72	3.42	-2.8	2.96	3.35	3.01	3.30	3.38	3.66	3.53	3.38	3.45	3.56	3.35	3.53	3.97	3.42	3.38	3.59
1										5																
rno-miR-36	1.15	2.54	2.38	2.44	-3.2	-3.2	-3.1	0.49	-3.2	-2.8	-3.3	-3.2	-3.2	-3.3	1.96	2.31	2.38	1.15	2.48	2.31	2.24	2.57	2.48	0.27	1.96	2.31
2*					1	6	4		3	5	2	9	9	0												
rno-miR-36	4.97	5.67	4.87	4.87	4.53	5.11	5.01	5.78	5.06	5.67	4.87	5.34	4.71	5.78	4.97	4.97	5.54	4.61	5.16	5.11	4.87	4.77	5.06	4.48	4.87	5.58

5																										
rno-miR-37	6.73	6.73	6.68	6.55	6.33	6.93	7.11	7.06	5.78	6.25	5.45	6.55	5.73	6.04	5.98	5.83	6.04	6.19	6.19	6.15	5.39	6.49	6.73	5.39	5.93	5.98
8																										
rno-miR-37	4.39	4.53	4.30	3.56	4.17	4.57	4.01	4.65	3.09	-2.8	-0.2	3.05	1.66	3.93	3.05	2.54	3.27	1.66	2.44	2.57	1.96	3.30	4.39	1.15	0.49	2.84
8*										5	3															
rno-miR-40	3.66	3.09	4.08	4.17	4.12	4.48	-3.1	3.16	3.48	5.39	3.66	4.35	4.08	3.48	4.57	4.48	2.90	3.59	4.30	4.57	4.61	4.12	4.30	3.56	4.17	3.35
9-3p							4																			
rno-miR-42	2.31	2.48	1.96	-3.2	-3.2	2.24	-3.1	2.44	-3.2	-2.8	-1.5	1.15	1.41	1.41	-3.2	1.96	2.44	2.54	2.24	2.44	0.72	-3.2	2.24	2.96	2.44	2.96
5				2	1		4		3	5	2				5							6				
rno-miR-42	2.84	1.96	-3.3	2.54	-3.2	-3.2	-3.1	2.54	3.59	4.04	3.59	2.94	2.38	2.44	3.63	3.45	3.56	4.12	2.96	3.93	3.48	2.61	1.15	4.08	4.25	3.09
9			2		1	6	4																			
rno-miR-45	6.04	6.09	5.93	6.99	5.58	5.06	5.34	5.34	6.15	5.93	5.16	5.39	7.16	6.33	6.55	6.40	7.80	5.98	6.33	5.28	5.93	6.04	5.45	5.01	5.54	5.78
1																										
rno-miR-45	0.27	-0.0	-2.5	-3.2	-3.2	-3.2	-3.1	2.84	-3.2	-2.8	-1.7	0.27	-3.2	-0.2	-3.2	-3.2	-1.7	-3.3	-3.2	-3.2	-3.2	-3.2	-3.2	-3.3	-3.3	-3.2
5*		3	3	2	1	6	4		3	5	4		9	3	5	9	4	1	4	5	9	6	9	2	1	7
rno-miR-46	5.67	2.44	3.16	3.97	5.01	5.49	4.17	3.23	4.48	6.33	5.93	4.77	5.11	4.74	2.57	2.44	-0.0	-3.3	-3.2	-3.2	2.94	-3.2	-3.2	3.09	-0.7	2.54
6b																	3	1	4	5		6	9		3	
rno-miR-46	-3.3	3.35	3.12	-3.2	-3.2	0.49	2.90	-0.7	-3.2	4.25	-3.3	-3.2	-0.3	3.09	-3.2	-0.7	-1.9	-3.3	-3.2	-3.2	-0.3	-3.2	-3.2	-2.5	-1.7	0.72
6b-1*	0			2	1			3	3		2	9	3		5	3	2	1	4	5	3	6	9	3	4	
rno-miR-46	-3.3	3.27	2.24	-3.2	-3.2	-3.2	-3.1	-3.2	-3.2	-2.8	-3.3	-3.2	-3.2	-3.3	-3.2	-3.2	0.27	-3.3	-3.2	-3.2	-0.0	-3.2	-3.2	2.90	2.54	3.63
6b-2*	0			2	1	6	4	9	3	5	2	9	9	0	5	9		1	4	5	3	6	9			
rno-miR-49	4.61	4.81	4.77	4.30	4.39	4.61	4.39	4.77	4.87	5.16	4.25	5.01	5.01	4.48	4.61	4.81	4.87	4.17	5.06	5.49	4.77	4.87	5.34	4.57	5.28	4.53
4																										
rno-miR-49	7.67	7.11	7.51	7.61	7.34	7.67	7.74	7.51	7.28	6.99	7.24	7.28	7.44	7.16	7.16	7.28	7.06	7.24	7.11	6.99	7.34	7.28	7.16	6.99	7.11	6.79
7																										
rno-miR-50	6.15	4.48	4.93	6.19	5.39	6.19	5.98	5.39	5.28	-2.8	5.73	5.58	5.93	4.87	3.59	4.57	3.68	2.94	2.90	2.96	4.44	4.57	4.57	4.35	3.01	3.68

0										5																
rno-miR-51	4.77	4.57	4.25	4.53	4.21	4.93	4.61	4.57	4.65	4.57	4.35	4.39	4.74	4.61	4.17	4.39	4.61	3.93	4.21	3.42	4.30	3.97	4.21	3.48	3.45	3.48
1*																										
rno-miR-53	3.16	2.90	2.90	3.19	2.44	2.90	-3.1	3.01	3.05	-2.8	1.41	2.44	2.61	1.96	3.27	3.23	3.01	3.09	3.01	3.19	3.23	3.19	3.16	2.94	2.94	3.05
2-5p							4			5																
rno-miR-54	-3.3	-0.2	2.54	-3.2	6.86	-3.2	-3.1	1.66	-3.2	-2.8	3.23	-3.2	-3.2	3.45	-3.2	-3.2	2.24	3.56	-3.2	-3.2	-3.2	4.21	-3.2	4.04	3.05	3.97
7	0	3		2		6	4		3	5		9	9		5	9			4	5	9		9			
rno-miR-58	-0.7	-3.3	3.27	2.38	3.48	3.93	2.94	-3.2	3.19	-2.8	3.38	3.66	3.45	-3.3	4.12	3.72	-3.3	2.61	3.66	4.12	4.01	-3.2	3.45	2.84	3.53	-3.2
2*	3	2						9		5				0			1					6				7
rno-miR-65	5.22	4.44	4.71	5.22	4.77	5.45	5.28	5.06	5.11	4.53	4.81	4.71	5.16	4.44	3.68	4.12	4.39	4.01	4.04	3.63	4.48	3.66	4.12	3.45	3.68	3.93
2																										
rno-miR-65	5.78	5.89	6.25	5.67	4.97	5.78	5.45	5.49	5.83	5.22	5.89	5.67	5.98	5.54	5.49	5.93	5.11	5.01	5.22	5.06	5.89	5.93	5.93	5.67	5.67	5.49
2*																										
rno-miR-67	-3.3	-2.6	-2.5	-3.2	-3.2	-3.2	-3.1	-0.3	-3.2	-2.8	-3.1	-3.2	-3.2	-3.3	-3.2	-3.2	-2.1	-2.3	1.41	-3.2	-0.7	-3.2	-3.2	-2.1	-1.1	1.15
4-3p	0	0	7	2	1	6	4	3	3	5	5	9	9	0	5	9	3	3		5	3	6	9	3	3	
rno-miR-70	3.42	2.57	3.68	4.08	7.96	4.44	-3.1	-3.2	4.12	5.06	4.04	4.48	3.97	-0.3	4.48	4.35	-3.3	3.72	4.25	4.39	4.53	4.17	4.25	3.63	4.08	-3.2
2-3p							4	9						3			1									7
rno-miR-74	3.97	2.94	4.21	4.74	-3.2	-3.2	4.81	4.17	-3.2	-2.8	4.74	3.72	-3.2	4.39	4.35	2.61	4.08	5.45	4.01	-3.2	1.41	5.45	4.53	5.78	4.57	4.97
3a					1	6			3	5			9							5						
rno-miR-7a	3.01	3.38	3.35	3.48	3.19	3.42	3.93	3.30	3.38	4.12	2.31	3.27	2.57	2.96	3.30	2.48	3.19	3.45	3.35	3.12	2.96	3.16	2.94	3.72	3.97	4.17
rno-miR-87	2.94	3.63	1.41	3.01	2.90	3.27	3.30	3.56	3.33	-2.8	2.24	2.61	2.84	2.57	2.96	2.90	2.94	3.48	3.33	2.61	3.01	3.01	2.84	3.35	2.57	3.27
2										5																
rno-miR-87	4.04	3.59	4.35	4.65	-3.2	-3.2	4.65	3.63	-3.2	-2.8	4.71	3.53	-3.2	4.53	4.21	4.21	3.48	4.57	3.68	3.59	3.12	5.22	4.48	4.97	4.61	4.57
8					1	6			3	5			9													
rno-miR-92	7.96	7.96	8.16	8.16	8.16	8.29	8.29	8.29	8.16	8.29	8.29	8.29	7.88	8.16	8.04	8.04	8.04	8.47	8.47	8.57	7.96	7.80	7.88	8.47	8.29	8.16
а																										

rno-miR-93	3.68	3.72	3.63	4.01	3.42	3.72	3.56	3.53	4.17	-2.8	3.56	3.68	3.53	3.63	4.04	3.93	3.63	4.87	4.81	4.74	3.68	3.42	3.66	4.74	4.97	4.44
										5																
rno-miR-96	3.27	3.19	-1.7	-3.2	-3.2	-3.2	-3.1	2.61	2.54	-2.8	1.66	-3.2	-3.2	-1.1	-3.2	2.24	3.12	2.38	-3.2	-3.2	-3.2	1.96	2.44	-3.3	3.30	2.24
			4	2	1	6	4			5		9	9	3	5				4	5	9			2		
rno-miR-98	4.35	4.74	4.53	4.39	4.04	4.81	4.74	4.71	4.81	4.93	4.57	4.65	4.81	4.57	4.65	4.77	4.74	4.30	4.48	4.87	4.71	4.01	4.44	4.39	4.39	4.39
rno-miR-99	8.04	7.74	7.96	7.96	7.61	8.16	7.96	7.96	8.29	7.80	8.16	8.16	8.29	8.29	8.16	8.47	8.16	7.88	7.96	8.04	8.16	8.16	7.96	7.74	7.96	7.96
а																										

Supplementary Table 2. Several miRNA-mRNA pairs involved in cell cycle regulation using IPA.

-		-			-			
Ν	ID	miRNA	Source	Confidence	ID	Sy	mRNA	cell cycle associated pathway
о.		FC				mbo	FC	
		(2/3				1	(2/3	
		vs 1/3)					vs 1/3)	
1	rno-miR-2	1.54	TargetScan	High	137	AR	-14.77	Integrin Signaling Paxillin Signaling
	5			(predicted)	901	F1	6	
					4_at			
2	rno-miR-2	1.54	TargetScan	High	136	CE	-4.712	Acute Myeloid Leukemia Signaling Glucocorticoid Receptor Signaling Growth Hormone Signaling Role of Macrophages,
	5			(predicted)	965	BP		Fibroblasts and Endothelial Cells in Rheumatoid Arthritis Tight Junction Signaling VDR/RXR Activation
					8_at	А		
3	rno-miR-2	1.54	TargetScan	High	139	KA	-2.829	AMPK Signaling Androgen Signaling Cell Cycle: G2/M DNA Damage Checkpoint Regulation Estrogen Receptor Signaling
	5			(predicted)	376	T2B		Glucocorticoid Receptor Signaling HMGB1 Signaling RAR Activation p53 Signaling
					2_at			
4	rno-miR-2	1.54	TargetScan	High	138	NFI	-2.696	Aryl Hydrocarbon Receptor Signaling
	5			(predicted)	825	В		
					0_at			

5	rno-miR-2	1.54	TargetScan	High	138	NFI	-7.799	Aryl Hydrocarbon Receptor Signaling
	5			(predicted)	121	х		
					3_at			
6	rno-miR-2	1.54	TargetScan	High	137	PR	-1.723	14-3-3-mediated Signaling Aldosterone Signaling in Epithelial Cells Amyloid Processing Androgen Signaling Apoptosis
	5			(predicted)	459	KC		Signaling Axonal Guidance Signaling Breast Cancer Regulation by Stathmin1 CCR3 Signaling in Eosinophils CCR5 Signaling
					3_at	Е		in Macrophages CREB Signaling in Neurons CXCR4 Signaling Calcium-induced T Lymphocyte Apoptosis
								Cholecystokinin/Gastrin-mediated Signaling Corticotropin Releasing Hormone Signaling Dopamine-DARPP32 Feedback in
								cAMP Signaling ERK/MAPK Signaling Endothelin-1 Signaling ErbB Signaling ErbB4 Signaling Erythropoietin Signaling
								Factors Promoting Cardiogenesis in Vertebrates Fc Epsilon RI Signaling Fcy Receptor-mediated Phagocytosis in Macrophages
								and Monocytes G Beta Gamma Signaling G-Protein Coupled Receptor Signaling GNRH Signaling Gap Junction Signaling
								Glioma Signaling Growth Hormone Signaling Gaq Signaling HER-2 Signaling in Breast Cancer HGF Signaling Hepatic
								Cholestasis Huntington's Disease Signaling IL-12 Signaling and Production in Macrophages IL-3 Signaling IL-8 Signaling
								LPS-stimulated MAPK Signaling Leukocyte Extravasation Signaling Macropinocytosis Signaling Mechanisms of Viral Exit
								from Host Cells Melatonin Signaling Molecular Mechanisms of Cancer NF-KB Activation by Viruses NRF2-mediated Oxidative
								Stress Response Natural Killer Cell Signaling Neuregulin Signaling Neuropathic Pain Signaling In Dorsal Horn Neurons P2Y
								Purigenic Receptor Signaling Pathway Phospholipase C Signaling Production of Nitric Oxide and Reactive Oxygen Species in
								Macrophages Prolactin Signaling Protein Kinase A Signaling Pyridoxal 5'-phosphate Salvage Pathway RAR Activation
								Renin-Angiotensin Signaling Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis Role of NFAT in
								Cardiac Hypertrophy Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses Salvage Pathways of
								Pyrimidine Ribonucleotides Sperm Motility Synaptic Long Term Depression Synaptic Long Term Potentiation Tec Kinase
								Signaling Thrombin Signaling Thrombopoietin Signaling Type II Diabetes Mellitus Signaling UVB-Induced MAPK Signaling
								UVC-Induced MAPK Signaling VDR/RXR Activation VEGF Family Ligand-Receptor Interactions Virus Entry via Endocytic
								Pathways Xenobiotic Metabolism Signaling fMLP Signaling in Neutrophils mTOR Signaling nNOS Signaling in Neurons
								p70S6K Signaling α-Adrenergic Signaling
7	rno-miR-2	1.54	Ingenuity Expert	Experimental	137	PTE	-1.552	3-phosphoinositide Biosynthesis 3-phosphoinositide Degradation B Cell Receptor Signaling D-myo-inositol
	5		Findings, TargetScan	ly	011	Ν		(1,3,4)-trisphosphate Biosynthesis D-myo-inositol (1,4,5,6)-Tetrakisphosphate Biosynthesis D-myo-inositol

-								
			Human	Observed, Hig	2_at			(3,4,5,6)-tetrakisphosphate Biosynthesis D-myo-inositol-5-phosphate Metabolism Endometrial Cancer Signaling Epithelial
				h (predicted)				Adherens Junction Signaling ErbB2-ErbB3 Signaling FAK Signaling Fcy Receptor-mediated Phagocytosis in Macrophages and
								Monocytes Glioblastoma Multiforme Signaling Glioma Signaling Hereditary Breast Cancer Signaling Hypoxia Signaling in the
								Cardiovascular System IL-17A Signaling in Airway Cells ILK Signaling Insulin Receptor Signaling Integrin Signaling
								Melanoma Signaling Neuregulin Signaling Ovarian Cancer Signaling PI3K Signaling in B Lymphocytes PI3K/AKT Signaling
								PTEN Signaling Prostate Cancer Signaling Protein Kinase A Signaling RAR Activation Role of Tissue Factor in Cancer Sertoli
								Cell-Sertoli Cell Junction Signaling Small Cell Lung Cancer Signaling Superpathway of D-myo-inositol (1,4,5)-trisphosphate
								Metabolism Superpathway of Inositol Phosphate Compounds Tight Junction Signaling iCOS-iCOSL Signaling in T Helper Cells
								p53 Signaling
8	rno-miR-2	1.54	TargetScan	High	138	PV	-5.782	Epithelial Adherens Junction Signaling Sertoli Cell-Sertoli Cell Junction Signaling Tight Junction Signaling
	5			(predicted)	821	RL1		
					5_at			
9	rno-miR-2	1.54	TargetScan	High	136	S1P	-3.034	Ceramide Signaling G-Protein Coupled Receptor Signaling Gai Signaling Human Embryonic Stem Cell Pluripotency
	5			(predicted)	907	R1		Sphingosine-1-phosphate Signaling cAMP-mediated signaling
					1_at			
1	rno-miR-2	1.54	TargetScan	High	139	SM	-2.237	BMP signaling pathway Protein Ubiquitination Pathway Regulation of the Epithelial-Mesenchymal Transition Pathway Role of
0	5			(predicted)	280	UR		Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis TGF-ß Signaling Tight Junction Signaling
					2_at	F1		
1	rno-miR-2	1.54	TargetScan	High	139	STA	-16.02	Mitotic Roles of Polo-Like Kinase
1	5			(predicted)	140	G2	4	
					4_at			
1	rno-miR-9	1.9/1.3	TargetScan	High	138	AL	-2.104	Aryl Hydrocarbon Receptor Signaling Dopamine Degradation Ethanol Degradation II Ethanol Degradation IV Fatty Acid
	3/rno-miR-			(predicted)	346	DH		α-oxidation Histamine Degradation LPS/IL-1 Mediated Inhibition of RXR Function Noradrenaline and Adrenaline Degradation
	106b				9_at	1A3		Oxidative Ethanol Degradation III Putrescine Degradation III RAR Activation Retinoate Biosynthesis I Serotonin Degradation
								Tryptophan Degradation X (Mammalian, via Tryptamine) Xenobiotic Metabolism Signaling
2	rno-miR-9	1.9/1.3	TarBase,TargetScan	Experimental	136	ARI	-1.784	DNA Methylation and Transcriptional Repression Signaling

	3/rno-miR-		Human,miRecords	ly	883	D4		
	106b			Observed, Hig	7_at	в		
				h (predicted)				
3	rno-miR-9	1.9/1.3	miRecords	Experimental	138	BC	-1.590	Amyotrophic Lateral Sclerosis Signaling Apoptosis Signaling Ceramide Signaling Cytotoxic T Lymphocyte-mediated Apoptosis
	3/rno-miR-			ly Observed	761	L2		of Target Cells Death Receptor Signaling Docosahexaenoic Acid (DHA) Signaling Glucocorticoid Receptor Signaling Hepatic
	106b				1_at			Fibrosis / Hepatic Stellate Cell Activation IL-15 Signaling IL-8 Signaling Induction of Apoptosis by HIV1 Interferon Signaling
								Melanocyte Development and Pigmentation Signaling Molecular Mechanisms of Cancer Myc Mediated Apoptosis Signaling
								Nur77 Signaling in T Lymphocytes OX40 Signaling Pathway Ovarian Cancer Signaling PEDF Signaling PI3K/AKT Signaling
								PTEN Signaling Pancreatic Adenocarcinoma Signaling Prostate Cancer Signaling Role of MAPK Signaling in the Pathogenesis
								of Influenza Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis Small Cell Lung Cancer Signaling
								TGF- β Signaling Type I Diabetes Mellitus Signaling VEGF Signaling p53 Signaling
4	rno-miR-9	1.9/1.3	TargetScan	High	138	CR	-23.09	ATM Signaling B Cell Receptor Signaling CREB Signaling in Neurons Calcium Signaling Circadian Rhythm Signaling
	3/rno-miR-			(predicted)	028	EB5	2	Corticotropin Releasing Hormone Signaling Dendritic Cell Maturation Dopamine-DARPP32 Feedback in cAMP Signaling
	106b				7_at			ERK/MAPK Signaling ERK5 Signaling Ephrin Receptor Signaling Estrogen-Dependent Breast Cancer Signaling FGF
								Signaling FLT3 Signaling in Hematopoietic Progenitor Cells G-Protein Coupled Receptor Signaling GNRH Signaling Gas
								Signaling Huntington's Disease Signaling Hypoxia Signaling in the Cardiovascular System ILK Signaling Melanocyte
								Development and Pigmentation Signaling NGF Signaling Neurotrophin/TRK Signaling P2Y Purigenic Receptor Signaling
								Pathway Phospholipase C Signaling Prostate Cancer Signaling Protein Kinase A Signaling Role of IL-17F in Allergic
								Inflammatory Airway Diseases Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis Synaptic Long
								Term Potentiation cAMP-mediated signaling p38 MAPK Signaling
5	rno-miR-9	1.9/1.3	TargetScan	High	139	KA	-2.829	AMPK Signaling Androgen Signaling Cell Cycle: G2/M DNA Damage Checkpoint Regulation Estrogen Receptor Signaling
	3/rno-miR-			(predicted)	376	T2B		Glucocorticoid Receptor Signaling HMGB1 Signaling RAR Activation p53 Signaling
	106b				2_at			
6	rno-miR-9	1.9/1.3	TargetScan	High	139	ME	-2.111	DNA Methylation and Transcriptional Repression Signaling
	3/rno-miR-			(predicted)	817	CP2		
	106b				4_at			

7	rno-miR-9	1.9/1.3	TargetScan	High	138	NFI	-2.696	Aryl Hydrocarbon Receptor Signaling
	3/rno-miR-			(predicted)	825	в		
	106b				0_at			
8	rno-miR-9	1.9/1.3	TargetScan	High	136	PPP	-1.745	AMPK Signaling Breast Cancer Regulation by Stathmin1 CDK5 Signaling CTLA4 Signaling in Cytotoxic T Lymphocytes
	3/rno-miR-			(predicted)	922	2R2		Cardiac β-adrenergic Signaling Cell Cycle Regulation by BTG Family Proteins Ceramide Signaling Cyclins and Cell Cycle
	106b				1_at	А		Regulation Dopamine Receptor Signaling Dopamine-DARPP32 Feedback in cAMP Signaling ERK/MAPK Signaling ILK
								Signaling Mitotic Roles of Polo-Like Kinase PI3K/AKT Signaling Production of Nitric Oxide and Reactive Oxygen Species in
								Macrophages Regulation of eIF4 and p70S6K Signaling Role of CHK Proteins in Cell Cycle Checkpoint Control Synaptic Long
								Term Depression Telomerase Signaling Tight Junction Signaling Wnt/β-catenin Signaling Xenobiotic Metabolism Signaling
								mTOR Signaling p70S6K Signaling
9	rno-miR-9	1.9/1.3	Ingenuity Expert	Experimental	137	PTE	-1.552	3-phosphoinositide Biosynthesis 3-phosphoinositide Degradation B Cell Receptor Signaling D-myo-inositol
	3/rno-miR-		Findings, TargetScan	ly	011	Ν		(1,3,4)-trisphosphate Biosynthesis D-myo-inositol (1,4,5,6)-Tetrakisphosphate Biosynthesis D-myo-inositol
	106b		Human	Observed, Hig	2_at			(3,4,5,6)-tetrakisphosphate Biosynthesis D-myo-inositol-5-phosphate Metabolism Endometrial Cancer Signaling Epithelial
				h (predicted)				Adherens Junction Signaling ErbB2-ErbB3 Signaling FAK Signaling Fcy Receptor-mediated Phagocytosis in Macrophages and
								Monocytes Glioblastoma Multiforme Signaling Glioma Signaling Hereditary Breast Cancer Signaling Hypoxia Signaling in the
								Cardiovascular System IL-17A Signaling in Airway Cells ILK Signaling Insulin Receptor Signaling Integrin Signaling
								Melanoma Signaling Neuregulin Signaling Ovarian Cancer Signaling PI3K Signaling in B Lymphocytes PI3K/AKT Signaling
								PTEN Signaling Prostate Cancer Signaling Protein Kinase A Signaling RAR Activation Role of Tissue Factor in Cancer Sertoli
								Cell-Sertoli Cell Junction Signaling Small Cell Lung Cancer Signaling Superpathway of D-myo-inositol (1,4,5)-trisphosphate
								Metabolism Superpathway of Inositol Phosphate Compounds Tight Junction Signaling iCOS-iCOSL Signaling in T Helper Cells
								p53 Signaling
1	rno-miR-9	1.9/1.3	Ingenuity Expert	High	138	RB	-1.674	Antiproliferative Role of TOB in T Cell Signaling Aryl Hydrocarbon Receptor Signaling Bladder Cancer Signaling Cell Cycle
0	3/rno-miR-		Findings,TarBase,Targ	(predicted)	818	1		Regulation by BTG Family Proteins Cell Cycle: G1/S Checkpoint Regulation Chronic Myeloid Leukemia Signaling Cyclins and
	106b		etScan		5_at			Cell Cycle Regulation Estrogen-mediated S-phase Entry Glioblastoma Multiforme Signaling Glioma Signaling Hereditary
			Human,miRecords					Breast Cancer Signaling Melanoma Signaling Molecular Mechanisms of Cancer Non-Small Cell Lung Cancer Signaling
								Ovarian Cancer Signaling Pancreatic Adenocarcinoma Signaling Prostate Cancer Signaling Regulation of Cellular Mechanics

								by Calpain Protease Role of BRCA1 in DNA Damage Response Role of Oct4 in Mammalian Embryonic Stem Cell Pluripotency
								Role of p14/p19ARF in Tumor Suppression Small Cell Lung Cancer Signaling Telomerase Signaling p53 Signaling
1	rno-miR-9	1.9/1.3	TargetScan	High	137	RN	-1.819	Actin Nucleation by ARP-WASP Complex CXCR4 Signaling Cardiac Hypertrophy Signaling Cholecystokinin/Gastrin-mediated
1	3/rno-miR-			(predicted)	766	D3		Signaling Colorectal Cancer Metastasis Signaling Germ Cell-Sertoli Cell Junction Signaling Glioblastoma Multiforme
	106b				3_at			Signaling Glioma Invasiveness Signaling Gaq Signaling HMGB1 Signaling IL-8 Signaling ILK Signaling Integrin Signaling
								Molecular Mechanisms of Cancer Phospholipase C Signaling Production of Nitric Oxide and Reactive Oxygen Species in
								Macrophages Regulation of Actin-based Motility by Rho RhoA Signaling RhoGDI Signaling Semaphorin Signaling in Neurons
								Signaling by Rho Family GTPases Sphingosine-1-phosphate Signaling Tec Kinase Signaling Thrombin Signaling mTOR
								Signaling
1	rno-miR-9	1.9/1.3	TargetScan	Experimental	136	S1P	-3.034	Ceramide Signaling G-Protein Coupled Receptor Signaling Gai Signaling Human Embryonic Stem Cell Pluripotency
2	3/rno-miR-			ly	907	R1		Sphingosine-1-phosphate Signaling cAMP-mediated signaling
	106b			Observed, Hig	1_at			
				h (predicted)				
1	rno-miR-9	1.9/1.3	TargetScan	High	139	SM	-2.237	BMP signaling pathway Protein Ubiquitination Pathway Regulation of the Epithelial-Mesenchymal Transition Pathway Role of
3	3/rno-miR-			(predicted)	280	UR		Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis TGF-ß Signaling Tight Junction Signaling
	106b				2_at	F1		
1	rno-miR-9	1.9/1.3	TargetScan	High	137	ST	-14.72	14-3-3-mediated Signaling AMPK Signaling mTOR Signaling
4	3/rno-miR-			(predicted)	536	K11	7	
	106b				4_at			
1	rno-miR-9	1.9/1.3	Ingenuity Expert	Experimental	136	TG	-1.679	Antiproliferative Role of TOB in T Cell Signaling Cardiac Hypertrophy Signaling Chronic Myeloid Leukemia Signaling
5	3/rno-miR-		Findings, TarBase, Targ	ly	965	FB		Colorectal Cancer Metastasis Signaling Epithelial Adherens Junction Signaling Factors Promoting Cardiogenesis in Vertebrates
	106b		etScan Human	Observed,Hig	3_at	R2		Germ Cell-Sertoli Cell Junction Signaling Glucocorticoid Receptor Signaling Hepatic Fibrosis / Hepatic Stellate Cell Activation
				h (predicted)				Human Embryonic Stem Cell Pluripotency Inhibition of Angiogenesis by TSP1 Molecular Mechanisms of Cancer NF-κB
								Signaling PPARa/RXRa Activation PTEN Signaling Pancreatic Adenocarcinoma Signaling Protein Kinase A Signaling
								Regulation of IL-2 Expression in Activated and Apergic T Lymphocytes Regulation of the Enithelial-Mesenchymal Transition
								Regulation of the 2 Expression in Activated and Anergie 1 Eynphoeyes Regulation of the Epitheman Mescheryman Hansholi

								Wnt/β-catenin Signaling p38 MAPK Signaling
1	rno-miR-9	1.9/1.3	TargetScan	High	138	TIA	-4.953	Actin Cytoskeleton Signaling Rac Signaling Tight Junction Signaling
6	3/rno-miR-			(predicted)	116	M1		
	106b				7_at			

Supplementary Methods

miRNA expression profiling using microarrays

Three samples for each type of surgery at each time point were used for microarray analysis. Total RNA was extracted and purified using the mirVana[™] miRNA Isolation Kit (Ambion) according to the manufacturer's instructions and was confirmed for the RIN number to inspect RNA integration using an Agilent Bioanalyzer 2100 (Agilent Technologies). The molecular miRNA within the total RNA was labeled by the miRNA Complete Labeling and Hyb Kit (Agilent Technologies) followed the manufacturer's instructions for labeling. Each slide was hybridized with 100 ng Cy3-labeled RNA using the miRNA Complete Labeling and Hyb Kit in hybridization Oven (Agilent Technologies) at 55 ℃, 20rpm for 20 hours according to the manufacturer's instructions for hybridization. After hybridization, the slides were washed in staining dishes (Thermo) with the Gene Expression Wash Buffer Kit (Agilent Technologies), and Feature Extraction software 10.7 (Agilent Technologies) was used with the default settings. Raw data were normalized against the Quantile algorithm, Gene Spring Software 11.0 (Agilent Technologies).

mRNA expression profiling using microarrays

Total mRNA was amplified, labeled and purified using the GeneChip 3'IVT Express Kit (Affymetrix) followed the manufacturer's instructions to obtain biotin labeled cRNA. Array hybridization and wash were performed using the GeneChip® Hybridization, Wash and Stain Kit (Affymetrix) in a Hybridization Oven 645 (Affymetrix) and with a Fluidics Station 450 (Affymetrix) according to the manufacturer's instructions. Slides were scanned using the GeneChip® Scanner 3000 (Affymetrix) and Command Console Software 3.1 (Affymetrix) with default settings. Raw data were normalized by MAS 5.0 algorithm in Gene Spring Software 11.0 (Agilent Technologies).

Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)

cDNA was synthesized from 10 ng of each RNA sample using the miScript II Reverse

Transcription Kit (Qiagen). PCR was performed using SYBR Green microRNA Assays. Rno-U6 snRNA served as the endogenous control. miRNA-specific primers were synthesized using Generay. The qRT-PCR was carried out on Applied Biosystems 7900HT Real-Time PCR System (AppliedBiosystem) using the Power SYBRH Green PCR Master Mix kit (Roche). The PCR conditions included an initial denaturation at 95 °C for 10 min, a two-step cycling conditions: 15 s denaturation at 95 °C and annealing/extension at 60 °C for 30 s, cycled 40 times. PCR reactions were performed in triplicate. The expression levels were calculated using the $\Delta \Delta Ct$ method.

Immunohistochemical staining and western blotting analyses

For immunohistochemical staining, bromodeoxyuridine (BrdU) was injected intraperitoneally (50 mg/kg) 2 hours prior to liver harvest to detect cells undergoing DNA synthsis. Harvested livers were embedded into paraffin blocks after fixation. Four µm paraffin sections were prepared on slides for BrdU, and Ki67 staining. Briefly, the slides were first deparaffinized by sequential treatment with xylene, 100% ethanol, 90% ethanol, 70% ethanol, 50% ethanol, distilled water, and PBS. To reveal BrdU labeling, the slides were then processed by using a BrdU staining kit (Invitrogen) according to the manufacturer's instructions. For Ki67 staining, the slides were incubated for 20 minutes in 1% H2O2 and washed 3 times with PBS. The slides were then blocked with a 1:2 dilution of fetal bovine serum for 1 hour. Tissue sections were treated with rabbit monoclonal Ki67 antibody at 1:200 with PBS containing blocking solution for 2 hours at 37 °C in a humidified chamber. After incubation, each slide was washed 3 times with PBS. A 1:300 dilution of horseradish peroxidase-labeled goat anti-rabbit antibody was incubated on the slides for 2 hours at 37 °C in a humidified chamber. The slides were then washed 3 times with PBS. The results were visualized via а reaction with diaminobenzidine (DAB, 3. 30-diaminobenzidine tetrahydrochloride) and counterstained with hematoxylin (Sigma). The number of cells that stained positively for BrdU per low-power field were quantified and expressed as the mean \pm the SEM for each group.

For western blotting analysis, cultured cells were collected in RIPA lysis buffer (50 mM Tris–HCl, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM PMSF) with 10 mg/ml protease inhibitor cocktail (Sigma). The extracted proteins were separated by SDS-PAGE and were transferred onto PVDF membranes. After being blocked by TBS-T buffer containing 5% non-fat milk powder for 2 hours, the membranes were immunoblotted using a primary antibody against RB1 (1:1500, Sigma) and KAT2B (1:1000, BAioworld). Immunoreactive bands on the blots were

visualized with an enhanced chemiluminescence reagent ECL kit (Beit Haemek).

Cell cycle and apoptosis analysis using flow cytometry

Two rat cell lines (BRL, normal hepatic cell line; RH-35, hepatoma cell line) were purchased from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China) and maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (Gibco) in a 37 $^{\circ}$ C incubator with 5% CO2. Cells were plated at a density of 3×105 cells per well of a 6-well Primaria plate (BD Bioscience). Twenty-four hours after seeding, the cells were transfected with control or miRNA mimics using HiPerFect Transfection Reagent (Qiagen) and the cells were collected 48 hours after transfection. For cell cycle analysis, 10^6 cells were re-suspended in 300 µl of PBS, and 700 µl ice cold ethanol to fix the cells overnight at -20 °C. Subsequently, the cells were washed twice with PBS and were then stained with 0.5 ml of DNA Prep Stain from the Coulter DNA-Prep Reagents kit (Beckman Coulter) at room temperature for 30 minutes in the dark followed by flow cytometry (BD Biosciences). The data were analyzed to calculate the percentage of the cell population in each phase using ModFit LT software. For apoptosis assay, cells were evaluated by using FITC-conjugated Annexin-V and Propidium Iodide (PI) kit according to the manufacturer's instructions and were analyzed using a flow cytometer and FlowJo software. APC-AnnexinV and 7-AAD staining were performed according to the manufacturer's instructions. Samples were analyzed using flow cytometry.

Adeno-associated virus (AAV) 9 preparation

miRNA precursor sequences of miR-106b~25 and sponges for these miRNAs were synthesized and confirmed by sequencing. The miRNA precursor and sponges were inserted in the plasmid pAOV-CMV-mCherry and pAOV-CMV-GFP, respectively (Neuronbiotech, Shanghai, China). As a negative control, an adenoviral vector expressing green fluorescent protein (GFP) or mCherry was constructed. AAV was produced by the transfection of 293T cells with 3 plasmids: an AAV vector (expressing the cluster, sponges, and their respective controls), an AAV helper plasmid (pAAV Helper) and an AAV Rep/Cap expression plasmid. At 72 h after transfection, the cells were collected and lysed using a freeze-thaw protocol. The viruses were purified using cesium chloride density gradient dialysis. All vector preparations were tittered by quantitative PCR using Taq-Man technology. The purity of the vectors was assessed by 4–12% SDS-acrylamide gel electrophoresis and silver

staining. The titer of the viruses was then determined by quantitative polymerase chain reaction (qPCR): 2×10^{12} -3 $\times 10^{12}$ infectious units per ml. The sequence of the miR-106b-25 was

catcactgcagcgtatgtggagatgaggcgagaggcccgggccagtaaggatgccacctacacttctgcccggaccctg etggccattetecgactttetactgeteggtgagtgetgggtecetgtetgetagaaggetgaccettgeetgecaccteace taatgtcettcaagetgcettetteeceteceagecetgetgggactaaagtgetgacagtgcagatagtggtcetetetgt gctaccgcactgtgggtacttgctgctccagcagggcacatgcaacacccacggagggaaaggctgcttgaatccacga gggctccaaagtgctgttcgtgcaggtagtgcattgcctgacctactgctgagctagcacttcccgagcccccaggacaca gcctctgacagtggccctagctgagcaccccaggctccacttgtcacgatggggagcctagtggagttcagaagggtctg gtctccctcacaggacggcaggacaccccaccgggactggccagtgttgagaggcggagacacgggcaattgctggacg tttgttctatgagtaggcgaatgtggcttgcccgggtttgaagccagagcagagatccttggtttcacccctcctcctcctatsequence of the sponges of miR-106b-25 was atctgcactgcgaagcactttagcagatctgcactgcgaagcactttagcagctacctgcactcaagcactttggcagtcagaccgagcacagtgcaatggcagctacctgcactcaagcactttggcagtcagaccgagcacagtgcaatggcagatctgc actgcgaagcactttagcagatctgcactgcgaagcactttagcagctacctgcactcaagcactttggcagtcagaccgagcacagtgcaatggcagctacctgcactcaagcactttggcagtcagaccgagcacagtgcaatggcagatctgcactgc gaagcactttagcagatetgcactgcgaagcaetttagcagctacctgcactcaagcaetttggcagtcagaccgagcaca $gtgcaatggcagctacctgcactcaagcactttggcagtcagaccgagcacagtgcaatggcag. \ 2 \times 1012 \ viral$ particles of adeno-associated virus (AAV) 9-miR-cluster, AAV9-miR-sponge, and their respective controls were separately injected into rats by way of tail vein.

Blood laboratory tests

Blood samples were obtained at animal sacrifice from the inferior vena cava in rats that had been injected with the AAV9 virus. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and the serum total bilirubin (T.Bil) levels were measured using standard laboratory methods.

Luciferase reporter assay

A total of 5×10^4 293T cells per well of a 24-well plate were seeded 1 day prior to transfection. Transfections were performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. For the luciferase assays, 293T cells were cotransfected with 10 nmol/L miRNA mimics or with the control or different pMIR-constructs. Transfected cells were assayed at 48 hours posttransfection and

firefly and Renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega). The relative luciferase activity was calculated as the ratio between the Renilla and firefly luciferase activities.